Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Mapp Biopharmaceutical Inc.
DescriptionCombination of 3 mAbs targeting Ebola glycoproteins GP1 and GP2
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationEbola
Indication DetailsTreat Ebola virus infection
Regulatory Designation U.S. - Fast Track (Treat Ebola virus infection);
U.S. - Orphan Drug (Treat Ebola virus infection)
PartnerDefyrus Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today